Literature DB >> 7664425

Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease.

R R Freedman1, R P Baer, M D Mayes.   

Abstract

BACKGROUND: Idiopathic Raynaud's disease is characterized by cold-induced digital vasospasms, but its origin has not been established. Previous research has shown that peripheral vascular alpha 2-adrenergic receptors are hypersensitive to local cooling in these patients, but the role of alpha 1-adrenergic receptors is not clear. Moreover, the role of adrenergic receptors in the production of actual vasospastic symptoms has not been investigated. METHODS AND
RESULTS: We studied 23 patients with idiopathic Raynaud's disease who were screened using conservative criteria. They were randomly assigned to receive brachial artery infusions of an alpha 1-antagonist, an alpha 2-antagonist, or both while vasospastic attacks were induced by cooling in the laboratory. Each patient's hands were photographed, and the number of attacks in the infused hand was compared with the number in the contralateral hand. The number of fingers (mean +/- SEM) with attacks in infused hands was yohimbine 0.3 +/- 0.3, prazosin 2.3 +/- 0.3, and both drugs 0.6 +/- 0.2. The difference between prazosin and the other two drug groups was significant (P < .001).
CONCLUSIONS: These findings demonstrate that activation of alpha 2-adrenergic receptors but not alpha 1-adrenergic receptors is necessary for the production of vasospastic attacks in idiopathic Raynaud's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664425     DOI: 10.1161/01.cir.92.6.1448

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod.

Authors:  Raffaela Bertoli; François Girardin; Stefan Russmann; Bernhard H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  2003-01-29       Impact factor: 2.953

Review 2.  Regulation of G protein-coupled receptor export trafficking.

Authors:  Chunmin Dong; Catalin M Filipeanu; Matthew T Duvernay; Guangyu Wu
Journal:  Biochim Biophys Acta       Date:  2006-09-23

Review 3.  Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

Review 4.  Intracellular α(2C)-adrenoceptors: storage depot, stunted development or signaling domain?

Authors:  Maqsood A Chotani; Nicholas A Flavahan
Journal:  Biochim Biophys Acta       Date:  2011-05-14

Review 5.  A vascular mechanistic approach to understanding Raynaud phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Nat Rev Rheumatol       Date:  2014-12-23       Impact factor: 20.543

6.  Molecular determinants of the human α2C-adrenergic receptor temperature-sensitive intracellular traffic.

Authors:  Catalin M Filipeanu; Ashok K Pullikuth; Jessie J Guidry
Journal:  Mol Pharmacol       Date:  2015-02-13       Impact factor: 4.436

7.  Modulation of α(2C) adrenergic receptor temperature-sensitive trafficking by HSP90.

Authors:  Catalin M Filipeanu; René de Vries; A H Jan Danser; Daniel R Kapusta
Journal:  Biochim Biophys Acta       Date:  2010-12-09

8.  The alpha2C-adrenoceptor deletion322-325 variant and cold-induced vasoconstriction.

Authors:  Eitan A Friedman; Paul A Harris; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Clin Auton Res       Date:  2009-05-15       Impact factor: 4.435

9.  Raynaud's phenomenon.

Authors:  Ashraful Haque; Michael Hughes
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

10.  Cyclic AMP acts through Rap1 and JNK signaling to increase expression of cutaneous smooth muscle alpha2C-adrenoceptors.

Authors:  A H Eid; M A Chotani; S Mitra; T J Miller; N A Flavahan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-16       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.